ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Neurology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1606702
Infantile Epileptic Spasm Syndrome: Predictors of Short-and Long-Term Outcomes
Provisionally accepted- 1Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
- 2King Fahad Hospital of the University, Al Khobar, Saudi Arabia
- 3Hospital Civil Fray Antonio Alcalde, Mexico, Mexico
- 4Department of Paediatrics, Division of neurology, Children’s Hospital of Western Ontario, Schulich School of Medicine & Dentistry. Western University, London, Canada
- 5Children’s Health Research Institute, London, Canada
- 6Department of Paediatrics, Division of Pediatric Neurology, Schulich School of Medicine & Dentistry. Western University, London, Canada
- 7Deparmtmet of Epidemiology and Statistics, Western University, London, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Infantile epileptic spasm syndrome (IESS) has significant impact on affected children that affects their future seizure control and neurodevelopmental outcomes. The aim of this study is to identify potential short- and long-term predictors of outcomes in children diagnosed IESS.Method: This retrospective study evaluated outcomes of seizure control and developmental status in a historical cohort of 60 children with IESS. The predictor variables included: age, treatment regimen, and early treatment response at 14 days, 3 and 6 months on the measured outcomes.Results: Among the 60 children in the cohort, 75% had identified etiologies: Genetic (40%), Structural (35%), and unknown causes (25%). Treatment interventions included either vigabatrin monotherapy (58.33%) or hormonal therapy with or without vigabatrin (41.67%). Clinical response at 3 and 6 months significantly correlated with good seizure control (p=0.008 and p=0.007, respectively) and favorable developmental outcome (p<0.001) at last follow-up. Logistic regression showed that treatment response at 3 months increased the odds of good seizure control by 7.21 times (95%CI=1.93 – 26.91, p=0.003), after adjusting for age, treatment regimen, and etiology. Genetic and structural etiologies were significantly associated with a higher likelihood of developing epileptic encephalopathy (EE), with odds ratios of 11.79 (95% CI=2.04–68.06, p=0.006) for genetic etiology and 10.21 (95% CI=1.75–59.65, p=0.010) for structural etiology.Discussion: Early treatment response at 3 and 6 months strongly predicts favorable seizure and developmental outcomes in IESS, with poor responders at these time points more likely to develop EE. Genetic and structural etiologies significantly influence EE risk, emphasizing the need for early identification, sustained treatment monitoring, and potential targeted interventions for high-risk subgroups.
Keywords: epileptic spasms, Outcome predictors, developmental epileptic encephalopathy, Infantile Epileptic Spasm Syndrome (IESS), developmental delay
Received: 06 Apr 2025; Accepted: 28 May 2025.
Copyright: © 2025 Al-Omari, Chavez, Miller, Prasad and Nabavi Nouri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mohammed A. Al-Omari, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.